Rauf Umaani, Ali Majid, Dehele Inderpal, Paudyal Vibhu, Elnaem Mohamed Hassan, Cheema Ejaz
School of Pharmacy, University of Birmingham, Birmingham, B15 2TT, UK.
Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.
J Pain Res. 2021 Aug 24;14:2601-2614. doi: 10.2147/JPR.S312227. eCollection 2021.
Mortalities due to fentanyl derivatives are on the rise with novel fentanyl analogues and still emerging on the global illicit drug market. They are highly potent and very fatal in low doses, yet there has been a lack of systematic research surrounding this subject. This review aims to assess the causes, nature, and toxicology of fatalities associated with fentanyl analogues.
Five databases: Scopus, Embase, Medline, PubMed and Google Scholar were searched from inception to October 2020 to identify case studies and case series reporting fentanyl analogue-related fatalities. Two independent reviewers screened and selected the articles followed by the data extraction from each article, which included demography, route of administration, causes and nature of death, and the fentanyl analogue implicated. All articles were then subject to quality assessment tools developed by the Joanna Briggs Institute (JBI). A narrative synthesis was undertaken.
The initial data search yielded 834 articles, only 14 of which met the inclusion criteria - this included nine case reports and five case series. Of the 1079 fentanyl-analogue related deaths reported, the majority of them occurred in the US (n=1044, 96.8%). The majority of fatalities were male (n=766, 71%), white (n=884, 87%) and in the age ranges 25-34 and 35-44 years (30.5% and 29.6%, respectively). The most common route of administration was intravenous (n=319, 66%) and the manner of death was almost exclusively accidental (99.7%). The predominant cause of death was fentanyl-analogue toxicity (n=292, 85.4%) and involved mixed drug toxicity (n=47, 13.7%). The mean post-mortem fentanyl analogue concentration was 31.6 ng/mL.
Most fatalities were reported in the US involving young white males. Overdose through intravenous administration and by mixed drug toxicities with other opioids were the major causes of death. Deaths reported in peer-reviewed literature were relatively less than those reported by real-world data.
随着新型芬太尼类似物的出现,因芬太尼衍生物导致的死亡人数不断上升,且在全球非法毒品市场上仍不断涌现。它们效力极强,低剂量即可致命,但围绕这一主题缺乏系统性研究。本综述旨在评估与芬太尼类似物相关死亡的原因、性质和毒理学。
检索了五个数据库:Scopus、Embase、Medline、PubMed和谷歌学术,检索时间从建库至2020年10月,以识别报告芬太尼类似物相关死亡的案例研究和病例系列。两名独立评审员筛选并选择文章,随后从每篇文章中提取数据,包括人口统计学、给药途径、死亡原因和性质,以及涉及的芬太尼类似物。然后,所有文章都采用乔安娜·布里格斯研究所(JBI)开发的质量评估工具进行评估。进行了叙述性综合分析。
初步数据检索产生了834篇文章,其中只有14篇符合纳入标准——这包括9篇病例报告和5篇病例系列。在报告的1079例与芬太尼类似物相关的死亡中,大多数发生在美国(n = 1044,96.8%)。大多数死亡者为男性(n = 766,71%)、白人(n = 884,87%),年龄在25 - 34岁和35 - 44岁之间(分别为30.5%和29.6%)。最常见的给药途径是静脉注射(n = 319, 66%),死亡方式几乎均为意外(99.7%)。主要死亡原因是芬太尼类似物中毒(n = 292, 85.4%),涉及混合药物中毒(n = 47, 13.7%)。尸检时芬太尼类似物的平均浓度为31.6 ng/mL。
大多数死亡报告发生在美国,涉及年轻白人男性。静脉注射过量以及与其他阿片类药物的混合药物中毒是主要死亡原因。同行评审文献中报告的死亡人数相对少于实际数据报告的人数。